Figure 6.
Figure 6. KRH3955 does not stimulate MPC mobilization in VEGF-A pretreated mice. (A-B) Mice were pretreated with VEGF-A or vehicle (dash) once daily on 4 consecutive days. Twenty-four hours after the last injection, mice were administered KRH3955 or vehicle (dash), and 2 h later, blood was collected for analysis of CXCL12 in PB plasma (A) and circulating CFU-Fs (B) (n = 5-7 mice per group). CXCL12 levels are shown as picograms per milliliter. CFU-Fs are shown as colonies per milliliter of blood. Data from 2 independent experiments are represented as mean ± SEM (one-way ANOVA with Bonferroni test). PT, pretreatment; VA, VEGF-A.

KRH3955 does not stimulate MPC mobilization in VEGF-A pretreated mice. (A-B) Mice were pretreated with VEGF-A or vehicle (dash) once daily on 4 consecutive days. Twenty-four hours after the last injection, mice were administered KRH3955 or vehicle (dash), and 2 h later, blood was collected for analysis of CXCL12 in PB plasma (A) and circulating CFU-Fs (B) (n = 5-7 mice per group). CXCL12 levels are shown as picograms per milliliter. CFU-Fs are shown as colonies per milliliter of blood. Data from 2 independent experiments are represented as mean ± SEM (one-way ANOVA with Bonferroni test). PT, pretreatment; VA, VEGF-A.

Close Modal

or Create an Account

Close Modal
Close Modal